Teladoc Health, Inc. Insider Trading Activity

Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock.

Accepted by SEC EDGAR 12/03/2025 - 09:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teladoc Health insider equity activity: A Teladoc Health officer, identified as President, International, reported routine equity compensation transactions involving company common stock. On December 1, 2025, the officer acquired 1,056 shares of Teladoc common stock through performance stock units converting on a one-for-one basis and an additional 3,101 shares and 4,556 shares through restricted stock units that also convert one-for-one into common stock. These awards stem from prior grants made in March 2023 and March 2024 with scheduled vesting over time.

On December 2, 2025, the officer sold 3,897 shares of Teladoc common stock at a price of $7.488 per share to cover tax withholding obligations related to the vesting of the performance and restricted stock units. Following these transactions, the officer continued to hold tens of thousands of Teladoc shares directly, reflecting ongoing equity ownership linked to prior stock unit grants.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Nueno Carlos

Role President, International

Sold 3,897 shs ($29K)

Approx. gross sale proceeds $29K

Approx. exercise cost $0.00

Share of Position Sold 12.5%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,897	$7.488	$29K
Exercise	Performance Stock Units	1,056	$0.00	$0.00
Exercise	Restricted Stock Units	3,101	$0.00	$0.00
Exercise	Restricted Stock Units	4,556	$0.00	$0.00
Exercise	Common Stock	1,056	$0.00	$0.00
Exercise	Common Stock	3,101	$0.00	$0.00
Exercise	Common Stock	4,556	$0.00	$0.00

Holdings After Transaction: Performance Stock Units — 1,061 contracts (Direct); Restricted Stock Units — 25,883 contracts (Direct); Common Stock — 27,175 shares (Direct)

Holdings Before and After: Performance Stock Units, 2,117 to 1,061 contracts (Direct); Restricted Stock Units, 33,540 to 25,883 contracts (Direct); Common Stock, 22,359 to 27,175 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (6)

1. F1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
2. F2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
3. F3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
4. F4. On March 1, 2024, the reporting person earned 12,679 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
5. F5. On March 3, 2023, the reporting person was granted 37,202 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
6. F6. On March 19, 2024, the reporting person was granted 54,675 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nueno Carlos

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, International

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		M		1,056	A	(1)	23,415	D
Common Stock	12/01/2025		M		3,101	A	(2)	26,516	D
Common Stock	12/01/2025		M		4,556	A	(2)	31,072	D
Common Stock	12/02/2025		S		3,897(3)	D	$7.488	27,175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	12/01/2025		M			1,056	(4)	(4)	Common Stock	1,056	$0	1,061	D
Restricted Stock Units	(2)	12/01/2025		M			3,101	(5)	(5)	Common Stock	3,101	$0	3,101	D
Restricted Stock Units	(2)	12/01/2025		M			4,556	(6)	(6)	Common Stock	4,556	$0	22,782	D

Explanation of Responses:

1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

4. On March 1, 2024, the reporting person earned 12,679 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

5. On March 3, 2023, the reporting person was granted 37,202 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

6. On March 19, 2024, the reporting person was granted 54,675 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.